Repligen (RGEN) Statistics

Repligen Corp (RGEN) is a bioprocessing company that provides products and services to improve the way biological drugs are made. As of September 30, 2021, the stock had a market capitalization of $17.34 billion. The company's stock has been performing well compared to the sector, with a year-to-date return of 77.6% as of November 17, 2021. This is significantly higher than the sector's return of 18.5%. Repligen Corp has been able to generate strong revenue per share, with the latest reported figure being $1.19. This indicates that the company is able to generate a decent amount of revenue for each outstanding share of stock.

The enterprise to EBITDA ratio, which measures the company's ability to generate income from its operations, was 137.96 as of September 30, 2021. This indicates that Repligen Corp is generating significant earnings before interest, taxes, depreciation, and amortization. The company has also maintained a healthy profit margin, with the latest reported figure being 35.4%. This indicates that Repligen Corp is able to generate a good amount of profit for each dollar of revenue. On the debt front, the company has managed to maintain a relatively low level of total debt, with the latest reported figure being $69.19 million. This indicates that Repligen Corp has a solid financial position and is not overly burdened by debt. The company has also recorded a strong gross profit, with the latest reported figure being $92.2 million. This indicates that Repligen Corp is able to generate a substantial amount of profit after deducting the cost of goods sold.